NATCOPHARM.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 19:00):

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs)...

Stats
本日の出来高	1.07M
平均出来高	1.05M
時価総額	176.42B
EPS	INR0 ( 2024-02-13 )
次の収益日	( INR0 ) 2024-05-27
Last Dividend	INR7.00 ( 2023-08-22 )
Next Dividend	INR0 ( N/A )
P/E	13.90
ATR14	INR0.917 (0.09%)

ボリューム相関

長: 0.00 (neutral)

短: 0.13 (neutral)

Signal:(32.64) Neutral

NATCO Pharma Limited 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

NATCO Pharma Limited 相関 - 通貨/商品

0.29
( neutral )

0.18
( neutral )

-0.50
( neutral )

-0.27
( neutral )

-0.63
( weak negative )

0.60
( weak )

NATCO Pharma Limited 財務諸表

Annual	2022
収益:	INR27.07B
総利益:	INR20.80B (76.83 %)
EPS:	INR39.18

FY	2022
収益:	INR27.07B
総利益:	INR20.80B (76.83 %)
EPS:	INR39.18

FY	2022
収益:	INR19.05B
総利益:	INR12.23B (64.22 %)
EPS:	INR9.32

FY	2021
収益:	INR16.90B
総利益:	INR10.82B (64.04 %)
EPS:	INR24.20

Financial Reports:

No articles found.

NATCO Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR3.50 (N/A)	INR0.750 (N/A)	INR1.250 (N/A)	INR0 (N/A)	INR7.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

NATCO Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 1.998 - low (50.00%) | Divividend Growth Potential Score: 3.28 - Decrease likely (34.42%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.200	1996-12-31
Last Dividend	INR7.00	2023-08-22
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	33	--
Total Paid Out	INR56.90	--
Avg. Dividend % Per Year	0.68%	--
Score	2.39	--
Div. Sustainability Score	1.998
Div.Growth Potential Score	3.28
Div. Directional Score	2.64	--

Next Divdend (Est)
(2024-07-24)

INR7.62 Estimate 6.47 %

Dividend Stability

0.26 Very Poor

Dividend Score

2.39

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1996	INR0	0.00%
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR8.50	1.07%
2019	INR7.00	1.01%
2020	INR8.75	1.42%
2021	INR3.50	0.36%
2022	INR6.25	0.68%
2023	INR8.25	1.49%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SIGIND.NS	Ex Dividend Junior	2023-09-22	Annually	11	0.62%
MAZDA.NS	Dividend Junior	2023-09-07	Annually	8	1.43%
GUFICBIO.NS	Dividend Junior	2023-09-21	Annually	20	0.04%
BASF.NS	Dividend Junior	2023-07-20	Annually	23	0.18%
PRECWIRE.NS	Dividend Junior	2023-08-28	Semi-Annually	23	1.28%
KALYANIFRG.NS	Dividend Junior	2023-09-13	Annually	17	0.81%
DYNAMATECH.NS	Dividend Junior	2023-06-09	Sporadic	17	0.10%
ADFFOODS.NS	Dividend Junior	2023-08-03	Sporadic	14	1.83%
STEELCAS.NS	Dividend Knight	2023-08-14	Bi-Monthly	3	0.88%
MURUDCERA.NS	Dividend Junior	2023-09-14	Sporadic	21	0.33%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.334	1.500	3.32	4.99	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.251	1.500	8.32	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	97.83	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	19.24	2.00	3.59	7.17	[0 - 30]
freeCashFlowPerShareTTM	19.24	2.00	0.380	0.760	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.783	1.000	0.290	0.290	[0.2 - 0.8]
operatingProfitMarginTTM	0.401	1.000	3.98	3.98	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.998

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.97	1.000	8.69	0	[1 - 100]
returnOnEquityTTM	0.251	2.50	8.92	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	19.24	2.00	3.59	0.760	[0 - 30]
dividendYielPercentageTTM	0.953	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	19.24	2.00	3.59	7.17	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-3.13	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0900	1.000	-0.250	0	[0.1 - 0.5]
Total Score				3.28

NATCO Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.